Glenmark Pharmaceuticals Ltd. (Glenmark) a research-led, global pharmaceutical company, launched TEVIMBRA® (tislelizumab) in India following the approval by Central Drugs Standard Control Organization (CDSCO). TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines), a global oncology leader committed to delivering advanced treatments for cancer patients worldwide. It is indicated for the […]
